share_log

康方生物：2023 年報

AKESO: 2023 ANNUAL REPORT

Hong Kong Stock Exchange ·  Apr 29 10:30
Summary by Moomoo AI
生物製藥公司AKESO於2023年12月31日結束的財年發布年度報告，顯示公司業績和治理的詳細情況。AKESO利用其ACE平台和Tetrabody技術開發了雙特異性抗體藥物，在腫瘤學、自身免疫和代謝疾病領域擁有超過50個創新項目，其中19個已進入臨床試驗階段，包括6個潛在的類別首創或最佳類別的雙特異性抗體。公司已商業化3種藥物，8項註冊臨床研究達到主要終點，包括全球首創的雙抗體Ivonescimab（PD-1/VEGF）和Cadonilimab（PD-1/CTLA-4）。Cadonilimab在2023年實現銷售額人民幣13.6億元，18個月累計銷售超過人民幣19億元。公司2023年度總收入為...展開全部
生物製藥公司AKESO於2023年12月31日結束的財年發布年度報告，顯示公司業績和治理的詳細情況。AKESO利用其ACE平台和Tetrabody技術開發了雙特異性抗體藥物，在腫瘤學、自身免疫和代謝疾病領域擁有超過50個創新項目，其中19個已進入臨床試驗階段，包括6個潛在的類別首創或最佳類別的雙特異性抗體。公司已商業化3種藥物，8項註冊臨床研究達到主要終點，包括全球首創的雙抗體Ivonescimab（PD-1/VEGF）和Cadonilimab（PD-1/CTLA-4）。Cadonilimab在2023年實現銷售額人民幣13.6億元，18個月累計銷售超過人民幣19億元。公司2023年度總收入為人民幣4526.3百萬元，較上年增長440%。年度毛利為人民幣4393.0百萬元，較上年增長491%，主要由於技術授權和合作收入的顯著增加。公司錄得年度利潤人民幣1942.4百萬元，而上一年度則虧損人民幣1422.2百萬元。年度財務報表由安永會計師事務所審計，公司建議在即將到來的年度股東大會上重新任命該會計師事務所。公司設有機制以確保向董事會提供獨立意見，包括定期的董事會評估和與管理層及其他董事成員的互動。董事會是集團的主要決策機構，負責監督業務、戰略決策和績效。所有董事為董事會的有效運作貢獻了豐富的商業經驗、知識和專業技能。公司在董事會下設立了三個委員會：審計委員會、薪酬委員會和提名委員會，每個委員會都有明確定義的書面職權範圍。公司未與董事或五位薪酬最高的個人進行任何重大交易，也未因董事加入或離開公司而向其支付任何款項。報告期間，公司未購買、出售或贖回任何已上市證券。公司的企業治理實踐與《企業治理守則》保持一致，唯一例外是董事長和首席執行官由同一人夏雨博士擔任，董事會認為這有利於強有力和一致的領導。公司旨在通過高效創新的研發成為全球領先的生物製藥企業。
BIOPHARMACEUTICAL COMPANY AKESO RELEASED ITS ANNUAL REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023, SHOWING DETAILS OF COMPANY PERFORMANCE AND GOVERNANCE. Using its ACE platform and Tetrabody technology, AKESO develops bi-specific antibody drugs with more than 50 innovative projects in oncology, autoimmune and metabolic diseases, 19 of which have entered clinical trials, including 6 potential class-first or best-in-class binomial antibodies. The company has commercialized 3 drugs and 8 registered clinical trials have reached major endpoints, including the world's first dual antibodies Ivonescimab (PD-1/VEGF) and Cadonilimab (PD-1/CTLA-4). Cadonilimab achieved sales of RMB 13.6 million in 2023, with cumulative sales exceeding RMB 19 billion in 18 months. The company's total revenue in 2023 was RMB4526.3 million, an increase of 440% over the previous year. Gross profit for...Show More
BIOPHARMACEUTICAL COMPANY AKESO RELEASED ITS ANNUAL REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023, SHOWING DETAILS OF COMPANY PERFORMANCE AND GOVERNANCE. Using its ACE platform and Tetrabody technology, AKESO develops bi-specific antibody drugs with more than 50 innovative projects in oncology, autoimmune and metabolic diseases, 19 of which have entered clinical trials, including 6 potential class-first or best-in-class binomial antibodies. The company has commercialized 3 drugs and 8 registered clinical trials have reached major endpoints, including the world's first dual antibodies Ivonescimab (PD-1/VEGF) and Cadonilimab (PD-1/CTLA-4). Cadonilimab achieved sales of RMB 13.6 million in 2023, with cumulative sales exceeding RMB 19 billion in 18 months. The company's total revenue in 2023 was RMB4526.3 million, an increase of 440% over the previous year. Gross profit for the year was RMB4393.0 million, an increase of 491% over the previous year, mainly due to a significant increase in technical licensing and collaboration revenues. The company recorded an annual profit of RMB1942.4 million, compared with a loss of RMB1422.2 million in the previous year. The annual financial statements are audited by EY, which proposes to reappoint the firm at the upcoming Annual General Meeting. The Company has mechanisms in place to ensure independent advice to the Board, including regular Board evaluations and interaction with management and other Board members. The Board of Directors is the Group's primary decision-making body responsible for overseeing business, strategic decision-making and performance. All directors contribute a wealth of business experience, knowledge and professional skills to the effective functioning of the Board. The Company has established three committees under the Board of Directors: the Audit Committee, the Remuneration Committee and the Nominating Committee, each of which has a clearly defined written mandate. The Company has not engaged in any major transactions with the Director or the highest five individuals, nor has he been paid any money as a result of the Director joining or leaving the Company. During the reporting period, the Company did not purchase, sell or redeem any listed securities. The company's corporate governance practices are consistent with the Code of Corporate Governance, with the only exception being that the Chairman and CEO are held by the same person, Dr. Xia Yu, who the Board believes is conducive to strong and consistent leadership. The company aims to become the world's leading biopharmaceutical company through efficient innovative research and development.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more